Pro-Dex (NASDAQ:PDEX) Research Coverage Started at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Pro-Dex (NASDAQ:PDEX) in a research note issued to investors on Wednesday. The firm set a “buy” rating on the medical instruments supplier’s stock.

Pro-Dex Price Performance

Shares of PDEX opened at $17.44 on Wednesday. The firm has a market cap of $61.91 million, a price-to-earnings ratio of 13.31 and a beta of 0.88. The stock has a 50 day moving average of $16.46 and a 200-day moving average of $17.26. The company has a current ratio of 3.79, a quick ratio of 1.83 and a debt-to-equity ratio of 0.27. Pro-Dex has a 52 week low of $14.51 and a 52 week high of $19.68.

Pro-Dex (NASDAQ:PDEX) last posted its quarterly earnings results on Friday, October 13th. The medical instruments supplier reported $0.42 EPS for the quarter. Pro-Dex had a net margin of 6.56% and a return on equity of 10.89%. The business had revenue of $10.64 million during the quarter.

Hedge Funds Weigh In On Pro-Dex

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Punch & Associates Investment Management Inc. boosted its position in Pro-Dex by 8.1% during the 3rd quarter. Punch & Associates Investment Management Inc. now owns 69,610 shares of the medical instruments supplier’s stock valued at $1,093,000 after purchasing an additional 5,235 shares during the period. Dimensional Fund Advisors LP boosted its position in Pro-Dex by 1.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 58,751 shares of the medical instruments supplier’s stock valued at $920,000 after purchasing an additional 625 shares during the period. LSV Asset Management boosted its holdings in shares of Pro-Dex by 13.9% during the first quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier’s stock valued at $588,000 after acquiring an additional 4,346 shares during the period. JPMorgan Chase & Co. grew its position in shares of Pro-Dex by 59.2% during the first quarter. JPMorgan Chase & Co. now owns 20,863 shares of the medical instruments supplier’s stock worth $345,000 after acquiring an additional 7,762 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Pro-Dex by 4.1% in the 2nd quarter. Northern Trust Corp now owns 19,735 shares of the medical instruments supplier’s stock worth $377,000 after acquiring an additional 776 shares during the period. 14.78% of the stock is currently owned by institutional investors and hedge funds.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.